Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative bacterial infections. However, limited safety and pharmacokinetic information is available. We investigated the safety and pharmacokinetics of intravenous polymyxin B in healthy subjects.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>An open-label, single-dose clinical trial was conducted in healthy Chinese subjects. Polymyxin B (sulphate) was administered intravenously at 0.75 or 1.5 mg/kg (<em>n</em>=10 per dose, 5 males and 5 females) to examine the safety and pharmacokinetics.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>One female subject in the 1.5-mg/kg group discontinued due to abdominal pain during administration. The most frequently reported adverse events were perioral paraesthesia, dizziness, and numbness of extremities (7/10 subjects in the 0.75-mg/kg group, all subjects in the 1.5-mg/kg group). All neurotoxicity-related events dissipated without treatment within a maximum of 23 h. Notably, abdominal pain (3/5) and vulvar pruritus (2/5), colpitis (2/5) or abnormal uterine bleeding (1/5) were reported in female subjects receiving the 1.5-mg/kg dose. In the 0.75-mg/kg group, the total clearance, volume of distribution and half-life of polymyxin B were 0.028±0.002 L/h/kg, 0.219±0.023 L/kg and 5.44±0.741 h, respectively; similar values were observed in the 1.5-mg/kg group. Urinary recovery was 3.7±1.1% and 8.1±1.3% in the 0.75- and 1.5-mg/kg groups, respectively. Population pharmacokinetics of polymyxin B was consistent with a three-compartment model. The clearance and distribution of the central compartment were 0.027 L/h/kg and 0.071 L/kg, respectively.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>This study is the first to examine the safety and pharmacokinetics of polymyxin B in healthy subjects. Our results highlight that acute toxicity is a dose-limiting factor for intravenous polymyxin B.</p>

Acute, subacute oral toxicity and Ames test of Py-mulin: an antibacterial drug candidate

Antimicrobial activity, safety and pharmacokinetics evaluation of PMTM: A novel pleuromutilin candidate

In Vitro and In Vivo Antibacterial Activity, Toxicity and Resistance Analysis of Pleuromutilin Derivative Z33 against Methicillin-Resistant Staphylococcus aureus

In Vitro and In Vivo Activity of 14- O-[(4,6-Diamino-pyrimidine-2-yl) thioacetyl] Mutilin against Methicillin-Resistant Staphylococcus aureus

Design, Synthesis and Biological Evaluation of Novel Pleuromutilin Derivatives Containing 6-Chloro-1-R-1H-pyrazolo[3,4-d]pyrimidine-4-amino Side Chain

Synthesis and antibacterial activities of novel pleuromutilin derivatives with a substituted pyrimidine moiety

Anti-methicillin-resistant Staphylococcus aureus activity and safety evaluation of 14-O-[(5-ethoxycarbonyl-4,6-dimethylpyrimidine-2-yl) thioacetyl] mutilin (EDT)

Mutagenicity and Safety Evaluation of Ethanolic Extract of Prunus Mume

Discovery of novel pleuromutilin derivatives as potent antibacterial agents

Β-Cypermethrin and Its Metabolite 3-Phenoxybenzoic Acid Exhibit Immunotoxicity in Murine Macrophages.

THE ACUTE TOXICITY AND BONE-MERROW MICRONUCLEUS TESTS OF WATER EXTRACT FROM Avicennia Marina FRUITS IN MICE

Preclinical Safety Evaluation of Oral Drug of Human Granulocyte-Macrophage Colony-Stimulating Factor Expressed in Silkworm Pupae As Bioreactor

Absence of in vitro genotoxicity of pyrvinium pamoate in sister-chromatid exchange, chromosome aberration, and HGPRT-locus mutation bioassays

Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects

Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO

Novel pleuromutilin derivatives with substituted 6-methylpyrimidine: Design, synthesis and antibacterial evaluation

Design, synthesis, and antibacterial activity of pleuromutilin derivatives

Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety

Design, synthesis, in vitro and in vivo evaluation against MRSA and molecular docking studies of novel pleuromutilin derivatives bearing 1, 3, 4-oxadiazole linker

Design, Synthesis and Antibacterial Evaluation of Pleuromutilin Derivatives

Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo